

Friday, October 16  
1310-1440

**Moderated ePosters 3**  
**Prostate Cancer: Epidemiology, Markers & Diagnostics**



**MP-03.01**

Comparative Analysis of Prostate Cancer Specific Biomarkers in Whole Urine, Urinary Sediment and Exosomes  
Rianne Hendriks, The Netherlands

**MP-03.02**

Validation of a New Urine Test for the Early Diagnosis of Clinically Significant Prostate Cancer  
Rianne Hendriks, The Netherlands

**MP-03.03**

Prospective Evaluation of the Utility of %p2PSA and the Prostate Health Index (PHI), in Predicting Prostate Cancer in Initial Prostate Biopsies of Singaporean Men, with Total PSA between 4.0 and 10ng/ml  
Benjamin Goh, Singapore

**MP-03.04**

Novel Molecular Targets of Curcumin Associated with Testosterone Metabolism in Prostate Cancer  
Hisamitsu Ide, Japan

**MP-03.05**

Effects on Prostate-Related Parameters and Incidence of Prostate Cancer (PCa) under Long-Term Therapy with Testosterone Undecanoate Injections (TU) in Hypogonadal Men for Up to 84 Months: Real-Life Experience from an Observational Registry Study  
Ahmad Haider, Germany

**MP-03.06**

Searching for Candidate Genes in Familial Prostate Cancer  
Nishanth Krishnananthan, Australia

**MP-03.07**

Is Prostate Cancer in Kenya the Most Aggressive in Africa? A Mortality Audit  
Mungai Ngugi, Kenya

**MP-03.08**

Prostate Cancer before Renal Transplantation: A Multicenter Study  
Xavier Tillou, France

**MP-03.09**

Diagnosis of Prostate Cancer as a Second Primary Cancer following a Melanoma Diagnosis: Are There Shared Risk Factors?  
Venu Chalasani, Australia

**MP-03.10**

A Comprehensive Study of Dicer and Its Related miRNAs in the Progression of Prostate Cancer  
Yijun Shen, China

**MP-03.11**

How Predictive of Prostate Cancer Are PIRADS 4 or 5 Lesions on MRI?  
Jonathan Cho, Australia

**MP-03.12**

Correlation between Multiparametric MRI Findings and Radical Prostatectomy Specimens  
Sean Huang, Australia

**MP-03.13**

The Use of 68 Gallium (GA) Prostate Specific Membrane Antigen (PSMA) Binding Ligand Positron Emission Tomography (PET) and Change in Clinical Management of Patients with Prostate Cancer  
Arjna Kanagarajah, Australia

**MP-03.14**

Global to Focal: The Changing Face of Prostate Cancer Diagnosis  
Henry Lewi, UK

**MP-03.15**

The Use of Circulating Tumour Cells in Delivery of Precision Medicine  
Handoo Rhee, Australia

**MP-03.16**

Transcriptionally-Targeted Retroviral Replicating Vectors: A Novel Strategy for Gene Therapy of Prostate Cancer  
Shuichi Kamijima, Japan